OBJECTIVE: The objective of this study is to review the evolution and changes of prostate cancer epidemiology and to perform an analysis of the current status of prostate cancer screening based on the various studies and scientific societies recommendations.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS: We performed a bibliographic review of relevant papers in relation to prostate cancer epidemiology and screening, with special focus on international and multicentric trials on population screening.
RESULTS: The current number and profile of patients being diagnosed of prostate cancer have changed significantly from the pre-PSA era to the present time. Early diagnosis and screening strategies have caused an increase in incidence and a decrease in cancer mortality in some countries.
CONCLUSIONS: Systematic screening, despite inconsistencies in some studies, seems to improve prostate cancer specific mortality. The introduction of new biomarkers, imaging techniques such as mpMRI as well as less aggressive therapeutic alternatives, probably open windows to the future for a better diagnosis and treatment of the disease.
Portela-Pereira P, Gómez-Veiga F. Are you the author?
Servicio de Urología, Complexo Universitario de Ourense, Ourense, España; Servicio de Urología, Hospital Universitario de Salamanca, Salamanca, España.
Reference: Arch Esp Urol. 2015 Apr;68(3):202-9.
Article in Spanish.